Leerink Swann Downgrades Array Biopharma (ARRY) to Market Perform; Phase II trial of ARRY-162 Results Poor
Tweet Send to a Friend
Leerink Swann downgrades Array Biopharma (Nasdaq: ARRY) from Outperform to Market Perform. Price target slashed from $6 to $2.
Leerink ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
